We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Large Genome-Wide Association Study Identifies Novel Abdominal Aortic Aneurysm Risk Loci

By LabMedica International staff writers
Posted on 05 Oct 2020
A recent report identified novel genetic associations for abdominal aortic aneurysm (AAA) with therapeutic implications and identified a subset of the population at significantly increased genetic risk of AAA that was independent of family history.

AAA is a localized enlargement of the abdominal aorta such that the diameter is greater than three centimeters or more than 50% larger than normal. More...
They usually cause no symptoms, except during rupture. Rupture may result in pain in the abdomen or back, low blood pressure, or loss of consciousness, and often results in death. AAAs occur most commonly in men over 50 years old, and among those with a family history. Additional risk factors include smoking, high blood pressure, and other heart or blood vessel diseases. AAAs are the most common form of aortic aneurysm. In the United States, screening with abdominal ultrasound is recommended for males between 65 and 75 years of age with a history of smoking. The genetic determinants of AAA remain incompletely defined. In total, 10 previously identified risk loci explain only a small fraction of the inheritance of AAA.

Investigators at Stanford University (Palo Alto, CA, USA) and a large number of collaborators from other institutions performed a genome-wide association study (GWAS) on samples obtained from the Million Veteran Program. This program, which was initiated in 2011 and is now one of the world's largest genetic biobanks, was designed to promote the study of how genes affect the health of United States military veterans.

For the current study, the investigators performed a GWAS on nearly 18 million DNA sequence variants with AAA (7,642 cases and 172,172 controls) in veterans of European ancestry with independent replication in up to 4,972 cases and 99,858 controls. They then used Mendelian randomization to examine the causal effects of blood pressure on AAA. In addition, they examined the association of AAA risk variants with aneurysms in the lower extremity, cerebral, and iliac arterial beds, and derived a genome-wide polygenic risk score (PRS) to identify a subset of the population at greater risk for the disease.

Results revealed 14 novel genetic loci, bringing the total number of known significant AAA loci to 24. A genetic-linked increase of 10 millimeters of mercury (Hg) in diastolic blood pressure increased the risk of developing abdominal aortic aneurysm. Analysis showed further that 19 of the 24 risk loci for AAA were associated with aneurysms in other parts of the body. A 29-variant PRS was strongly associated with AAA, independent of family history and smoking risk factors. Using this PRS, the investigators identified a subset of the population with AAA prevalence greater than that observed in screening trials performed according to current guidelines.

"This study has doubled the number of genetic associations with abdominal aortic aneurysm, adding greatly to our understanding of the disease mechanisms," said senior author Dr. Philip S. Tsao, professor of cardiovascular medicine at Stanford University. "We were surprised that diastolic blood pressure, as opposed to systolic blood pressure, is likely of greater significance in the development of abdominal aortic aneurysm. This new information can enhance screening protocols and help identify individuals at risk for abdominal aortic aneurysm."

The AAA study was published in the September 28, 2020, online edition of the journal Circulation.

Related Links:
Stanford University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study design and workflow (Parankusham H, Vanderlip C, Birkenbihl C, et al. A two-stage plasma biomarker algorithm reduces amyloid PET use and the p-Tau217 gray zone. Annals of Clinical and Translational Neurology. Published online October 19, 2026. doi:10.1002/acn3.70560)

Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment

Blood-based biomarkers offer a more accessible, less expensive way to detect Alzheimer’s-related brain changes than traditional methods such as amyloid-beta positron emission tomography (Aβ-PET).... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.